keyword
https://read.qxmd.com/read/38538921/impact-of-aripiprazole-discontinuation-in-remitted-major-depressive-disorder-a-randomized-placebo-controlled-trial
#21
JOURNAL ARTICLE
Masahiro Takeshima, Akise Umakoshi, Yuki Omori, Kazuhisa Yoshizawa, Masaya Ogasawara, Mizuki Kudo, Yu Itoh, Naoko Ayabe, Kazuo Mishima
RATIONALE: The efficacy and safety of antidepressant augmentation therapy with aripiprazole (AATA) has been established; however, the ongoing effects of continuing aripiprazole after remission remain unclear because no studies have examined this issue. OBJECTIVES: We aimed to explore the effect of AATA discontinuation on the major depressive disorder (MDD) recurrence risk in patients with remitted MDD after AATA. METHODS: This 24-week, multicenter, placebo-controlled, double-blind, randomized trial evaluated recurrence risk in patients with MDD who achieved remission with AATA...
March 28, 2024: Psychopharmacology
https://read.qxmd.com/read/38534050/antipsychotic-use-and-psychiatric-hospitalization-in-first-episode-non-affective-psychosis-and-cannabis-use-disorder-a-swedish-nationwide-cohort-study
#22
JOURNAL ARTICLE
Alexander Denissoff, Heidi Taipale, Jari Tiihonen, Marta Di Forti, Ellenor Mittendorfer-Rutz, Antti Tanskanen, Antti Mustonen, Solja Niemelä
BACKGROUND AND HYPOTHESIS: There is a paucity of research on treatment outcomes of patients with psychosis and cannabis use disorder (CUD). We aimed to compare the effectiveness of antipsychotics in reducing the risk of hospitalization in patients with first-episode psychosis (FEP) and co-occurring CUD. STUDY DESIGN: We utilized a nationwide Swedish cohort of patients with longitudinal register data from the year 2006 to 2021. Participants were patients with FEP and co-occurring CUD (n = 1820, 84...
March 26, 2024: Schizophrenia Bulletin
https://read.qxmd.com/read/38526396/clinical-experience-on-the-use-of-a-single-day-two-injection-start-initiation-regimen-of-aripiprazole-once-monthly-in-patients-with-schizophrenia-in-spain-satisfy-study
#23
JOURNAL ARTICLE
Miquel Bioque, María José Moreno, Susana Gómez-Lus, María Isabel Ramos
OBJECTIVE: The two-injection start (TIS) initiation regimen was recently approved for aripiprazole once monthly 400 mg (AOM400), with potential benefits in adherence. The SaTISfy study described in this article analyzed Spanish psychiatrists' perspectives on hospitalization lengths of stay, schizophrenia management, and the use of AOM400-TIS. METHODS: The authors describe an ecological study of aggregated data collected using a 41-question survey. Fifty psychiatrists were asked to provide their perceptions of their patients with schizophrenia and treatment with AOM400...
March 1, 2024: Journal of Psychiatric Practice
https://read.qxmd.com/read/38517161/resolution-of-severe-neurobehavioral-difficulties-in-an-individual-with-primrose-syndrome-with-sertraline
#24
Young Min Moon, Sa Eun Park, Constance Smith-Hicks, Aaron Hauptman
Primrose syndrome (PS) is a rare genetic disease characterized by developmental delay, intellectual disability, sensorineural hearing loss, and dysmorphic features. PS is caused by de novo pathogenic variants in the ZBTB20 gene, which encodes a transcription factor modulating neurogenesis. We describe resolution with sertraline of neurobehavioral difficulties in a 17-year-old Hispanic male with PS with de novo heterozygous c.1916G > A (p.C639Y) variant of ZBTB20. Neurobehavioral difficulties included aggression towards self and others, irritability, tearfulness, and mood liability that did not respond to behavioral interventions or aripiprazole...
March 22, 2024: American Journal of Medical Genetics. Part A
https://read.qxmd.com/read/38516460/a-case-of-postpartum-obsessive-compulsive-disorder-in-a-first-time-father
#25
Kevin W Chen, Luke Schultz, Neil Hughes
Obsessive-Compulsive Disorder (OCD) is a well-recognized psychiatric condition characterized by distressing obsessions and compulsions. While the perinatal period is a known trigger for OCD in women, less attention has been given to its occurrence in men, particularly new fathers. This case report examines the unique presentation of postpartum-onset OCD (ppOCD) in a first-time father. A 33-year-old father presented eight months after the birth of his first child with distressing intrusive thoughts related to harming his eight-month-old daughter...
February 2024: Curēus
https://read.qxmd.com/read/38505795/treatment-of-antipsychotic-induced-hyperprolactinemia-an-umbrella-review-of-systematic-reviews-and-meta-analyses
#26
REVIEW
Qitong Jiang, Tian Li, Lei Zhao, Yue Sun, Zhen Mao, Yujie Xing, Chuanyue Wang, Qijing Bo
BACKGROUND: Hyperprolactinemia is a common antipsychotic-induced adverse event in psychiatric patients, and the quality of clinical studies investigating the best treatments has varied. Thus, to better summarize the clinical evidence, we performed an umbrella review of overlapping systematic reviews and meta-analyses for the treatment of antipsychotic-induced hyperprolactinemia. METHODS: The PubMed, Cochrane Library, PsycINFO, Scopus and EMBASE were searched, and reviews and meta-analyses meeting our inclusion criteria were selected...
2024: Frontiers in Psychiatry
https://read.qxmd.com/read/38502910/successful-clozapine-rechallenge-after-clozapine-induced-severe-anemia-a-case-report
#27
JOURNAL ARTICLE
Felipe Mendonça Rocha Barros, Arthur Cardoso Tolentino, Lais Soares Ker Marques, Leandro Xavier de Camargo Schlittler, Karina Diniz Oliveira, Paulo Dalgalarrondo, Lucas Luchesi Barnes, Amilton Dos Santos Junior, Claudio Eduardo Muller Banzato
INTRODUCTION: Clozapine, a second-generation antipsychotic (SGA), is considered the gold standard medication to treat patients with treatment-resistant schizophrenia (TRS). Despite its efficacy, clozapine is associated with adverse effects, notably neutropenia and agranulocytosis. Other hematological adverse effects are less common. Severe anemia is a rare adverse effect seldom reported in the literature and is typically associated with pure red cell aplasia (PRCA). Nevertheless, the benefits of clozapine in managing TRS make rechallenge a reasonable option...
March 19, 2024: Schizophrenia Bulletin
https://read.qxmd.com/read/38500267/the-effective-perospirone-augmentation-with-clonazepam-for-treatment-resistant-burning-mouth-syndrome-a-case-report
#28
Motoko Watanabe, Chihiro Takao, Chizuko Maeda, Gayatri Nayanar, Risa Tominaga, Yasuyuki Kimura, Trang Thi Huyen Tu, Takahiko Nagamine, Akira Toyofuku
Burning mouth syndrome (BMS) is characterized by burning sensations in the oral region without corresponding abnormalities and is often accompanied by uncomfortable sensations. Herein, we present cases of BMS in which the remaining uncomfortable sensations improved with perospirone augmentation with clonazepam. Case 1: A 61-year-old man complained of a burning pain in his tongue, a sensation of dryness and discomfort as if his tongue was sticking to a palatal plate. With the diagnosis of BMS, psychopharmacotherapy was initiated with amitriptyline...
March 18, 2024: Neuropsychopharmacology Reports
https://read.qxmd.com/read/38497965/development-and-validation-of-a-machine-learning-based-model-of-mortality-risk-in-first-episode-psychosis
#29
JOURNAL ARTICLE
Johannes Lieslehto, Jari Tiihonen, Markku Lähteenvuo, Stefan Leucht, Christoph U Correll, Ellenor Mittendorfer-Rutz, Antti Tanskanen, Heidi Taipale
IMPORTANCE: There is an absence of mortality risk assessment tools in first-episode psychosis (FEP) that could enable personalized interventions. OBJECTIVE: To examine the feasibility of machine learning (ML) in discerning mortality risk in FEP and to assess whether such risk predictions can inform pharmacotherapy choices. DESIGN, SETTING, AND PARTICIPANTS: In this prognostic study, Swedish nationwide cohort data (from July 1, 2006, to December 31, 2021) were harnessed for model development and validation...
March 4, 2024: JAMA Network Open
https://read.qxmd.com/read/38495608/functioning-and-cognition-in-patients-with-schizophrenia-after-initiating-treatment-with-aripiprazole-lauroxil-secondary-outcomes-and-post-hoc-analysis
#30
JOURNAL ARTICLE
Mark G A Opler, Amy Claxton, James McGrory, Sabina Gasper, Meihua Wang, Sergey Yagoda
BACKGROUND: Clinical practice guidelines support efforts to improve functioning in patients with schizophrenia. Discrepancies in the perception of cognitive status between clinicians, patients with schizophrenia, and their caregivers have been associated with impaired functional abilities in patients; medication side effects might worsen both cognition and daily functioning. We assessed daily/social functioning and cognition in stable patients with schizophrenia who switched to the long-acting injectable (LAI) antipsychotic aripiprazole lauroxil (AL)...
2024: Innovations in Clinical Neuroscience
https://read.qxmd.com/read/38495124/analysis-of-medicare-patients-treated-with-pimavanserin-versus-other-atypical-antipsychotics-a-cost-offset-model-evaluating-skilled-nursing-facility-stays-and-long-term-care-admissions-in-parkinson-s-disease-psychosis
#31
JOURNAL ARTICLE
Krithika Rajagopalan, Nazia Rashid, Vinod Yakkala, Dilesh Doshi
BACKGROUND: Patients with Parkinson's disease psychosis (PDP) treated with pimavanserin (PIM) versus other atypical antipsychotics (AAPs) including quetiapine (QUE) may have health-care cost savings due to fewer skilled nursing facility-stays (SNF-stays) and long-term care admissions (LTCA). METHODS: A decision analytic model was developed using the 2019 Medicare Patient Driven Payment Model (PDPM) to estimate SNF-stays and LTCA associated per-patient- per-year (PPPY) facility and rehabilitation costs among patients that initiated PIM vs QUE or vs other-AAPs (i...
2024: ClinicoEconomics and Outcomes Research: CEOR
https://read.qxmd.com/read/38494658/proportion-of-antipsychotics-with-cyp2d6-pharmacogenetic-pgx-associations-prescribed-in-an-early-intervention-in-psychosis-eip-cohort-a-cross-sectional-study
#32
JOURNAL ARTICLE
Adam Jameson, Muhammad Faisal, Beth Fylan, Greg C Bristow, Jaspreet Sohal, Caroline Dalton, Gurdeep S Sagoo, Alastair G Cardno, Samantha L McLean
BACKGROUND: Prescribing drugs for psychosis (antipsychotics) is challenging due to high rates of poor treatment outcomes, which are in part explained by an individual's genetics. Pharmacogenomic (PGx) testing can help clinicians tailor the choice or dose of psychosis drugs to an individual's genetics, particularly psychosis drugs with known variable response due to CYP2D6 gene variants ('CYP2D6-PGx antipsychotics'). AIMS: This study aims to investigate differences between demographic groups prescribed 'CYP2D6-PGx antipsychotics' and estimate the proportion of patients eligible for PGx testing based on current pharmacogenomics guidance...
March 17, 2024: Journal of Psychopharmacology
https://read.qxmd.com/read/38490016/efficacy-acceptability-and-side-effects-of-oral-versus-long-acting-injectables-antipsychotics-systematic-review-and-network-meta-analysis
#33
REVIEW
Dongfang Wang, Johannes Schneider-Thoma, Spyridon Siafis, Mengchang Qin, Hui Wu, Yikang Zhu, John M Davis, Josef Priller, Stefan Leucht
Long-acting injectable antipsychotics (LAIs) are primarily used for relapse prevention, but in some settings and situations, they may also be useful for acute treatment of schizophrenia. We conducted a systematic review and frequentist network meta-analysis of randomized-controlled trials (RCTs), focusing on adult patients in the acute phase of schizophrenia. Interventions were risperidone, paliperidone, aripiprazole, olanzapine, and placebo, administered either orally or as LAI. We synthesized data on overall symptoms, complemented by 17 other efficacy and tolerability outcomes...
March 14, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://read.qxmd.com/read/38485677/assessment-of-monitoring-and-management-practices-of-antipsychotic-induced-hyperprolactinemia-at-a-medical-city-in-riyadh-saudi-arabia-a-retrospective-cohort-study
#34
JOURNAL ARTICLE
Zahra Hussain Alshabeeb, Bashayr Alsuwayni, Omar Alshargi, Ahmed H Abdelazeem
BACKGROUND: Hyperprolactinemia is a commonly underestimated adverse effect of antipsychotic medications. There are still no consensus guidelines for the optimal monitoring and treatment strategies. OBJECTIVE: The aim of the study was to assess the monitoring and treatment practices of antipsychotic- induced hyperprolactinemia, in addition to the prevalence and risk factors associated with it. METHODS: A retrospective cohort observational study was conducted among patients attending the psychiatric clinics at an academic tertiary hospital in Riyadh, Saudi Arabia, from May 2020 until May 2021, by reviewing each patient's medical record for up to five years...
March 12, 2024: Current Drug Safety
https://read.qxmd.com/read/38469209/effects-of-aripiprazole-on-olanzapine-population-pharmacokinetics-and-initial-dosage-optimization-in-schizophrenia-patients
#35
JOURNAL ARTICLE
Cun Zhang, Lei Jiang, Ke Hu, Liang Chen, Yi-Jia Zhang, Hao-Zhe Shi, Su-Mei He, Xiao Chen, Dong-Dong Wang
OBJECTIVE: Olanzapine has already been used to treat schizophrenia patients; however, the initial dosage recommendation when multiple drugs are used in combination, remains unclear. The purpose of this study was to explore the drug-drug interaction (DDI) of multiple drugs combined with olanzapine and to recommend the optimal administration of olanzapine in schizophrenia patients. METHODS: In this study, we obtained olanzapine concentrations from therapeutic drug monitoring (TDM) database...
2024: Neuropsychiatric Disease and Treatment
https://read.qxmd.com/read/38465894/long-acting-second-generation-injectable-antipsychotics-for-the-maintenance-treatment-of-bipolar-disorder-a-narrative-review
#36
REVIEW
Jean-Baptiste Belge, Bernard G C C Sabbe
INTRODUCTION: Non-adherence to medication significantly affects bipolar disorder outcomes. Long-Acting Injectable antipsychotics show promise by ensuring adherence and averting relapses. AREAS COVERED: This narrative review sought to evaluate the efficacy of second-generation injectable antipsychotics in bipolar disorder through searches in Embase, MEDLINE, and PsycInfo for randomized controlled trials and mirror-image studies.Risperidone and aripiprazole Long-Acting Injectables demonstrated effectiveness in preventing mood recurrences compared to placebos in adults with bipolar disorder...
March 11, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38461611/a-case-report-of-lai-two-injection-start-in-a-16-year-old-adolescent-with-severe-manic-episode-and-comorbid-cannabinoid-use-disorder
#37
JOURNAL ARTICLE
Laura Orsolini, Sofia Pacini Biagiotti, Lorenzo Maria Martino, Umberto Volpe
There is a lack of randomized clinical trials and few studies regarding long-acting injectable antipsychotics (LAIs) in adolescents. Non-adherence, aggressiveness, comorbid substance use disorder and lack of insight may represent the main reasons for starting LAIs. Hereby we describe a 16-year-old male adolescent subject with bipolar type I disorder and comorbid cannabinoid use disorder, successfully treated with two-injection start regimen of LAI aripiprazole. Two-injection start regime of aripiprazole could represent an effective and safe therapeutic option for adolescents with early onset bipolar disorder...
March 4, 2024: Asian Journal of Psychiatry
https://read.qxmd.com/read/38454079/comparative-effectiveness-research-trial-for-antidepressant-incomplete-and-non-responders-with-treatment-resistant-depression-ascertain-trd-a-randomized-clinical-trial
#38
JOURNAL ARTICLE
George I Papakostas, Madhukar H Trivedi, Richard C Shelton, Dan V Iosifescu, Michael E Thase, Manish K Jha, Sanjay J Mathew, Charles DeBattista, Mehmet E Dokucu, Olga Brawman-Mintzer, Glenn W Currier, William Vaughn McCall, Mandana Modirrousta, Matthew Macaluso, Alexander Bystritsky, Fidel Vila Rodriguez, Erik B Nelson, Albert S Yeung, Anna Feeney, Leslie C MacGregor, Thomas Carmody, Maurizio Fava
Further research is needed to help improve both the standard of care and the outcome for patients with treatment-resistant depression. A particularly critical evidence gap exists with respect to whether pharmacological or non-pharmacological augmentation is superior to antidepressant switch, or vice-versa. The objective of this study was to compare the effectiveness of augmentation with aripiprazole or repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine XR (or duloxetine for those not eligible to receive venlafaxine) for treatment-resistant depression...
March 7, 2024: Molecular Psychiatry
https://read.qxmd.com/read/38450551/impact-of-preoperative-aripiprazole-on-postoperative-analgesia-in-laparoscopic-hysterectomy-a-randomized-double-blind-placebo-controlled-trial
#39
JOURNAL ARTICLE
Amin Mohamed Alansary, Marwa Ahmed Khairy Elbeialy
OBJECTIVES: Aripiprazole is a second-generation atypical antipsychotic with worldwide clinical approval. Nevertheless, its perioperative antinociceptive application has not been studied. As a result, the purpose of this study was to investigate the analgesic effects of perioperative aripiprazole on reducing postoperative pain, as well as the possible adverse effects. METHODS: This randomized controlled study enrolled eighty female patients scheduled for laparoscopic hysterectomy who were assigned randomly into two equal groups in 1:1; Aripiprazole group (n=40): patients received an aripiprazole 30 mg tablet orally three hours before surgery, and Placebo group (n=40): patients received a placebo tablet three hours before surgery...
March 7, 2024: Clinical Journal of Pain
https://read.qxmd.com/read/38437955/mechanisms-of-adverse-mammary-effect-induced-by-olanzapine-and-therapeutic-interventions-in-rat-model
#40
JOURNAL ARTICLE
Yingyue Dong, Xiaozhe Sun, Hanxiao Li, Chunmiao Han, Yue Zhang, Huiru Ding, Lisha Xia, Huamin Wang, Shaomin Yang, Lingzi Xu, Guoheng Xu
BACKGROUND: Olanzapine antagonizes dopamine receptors and is prescribed to treat multiple psychiatric conditions. The main side effect of concern for olanzapine is weight gain and metabolic syndrome. Olanzapine induces hyperprolactinemia, however its effect on the mammary gland is poorly documented. METHODS: Rats received olanzapine by gavage or in drinking water at 1, 3, and 6 mg/kg/day for 5-40 days or 100 days, with and without coadministration of bromocriptine or aripiprazole and using once daily or continuous administration strategies...
March 2, 2024: Toxicology and Applied Pharmacology
keyword
keyword
4828
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.